id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-280697-tovty20e	Rodríguez‐Martínez, Carlos E.	Efficacy, safety and cost‐effectiveness of hydroxychloroquine in children with COVID‐19: A call for evidence	2020-06-03		.txt	text/plain	929	55	48	Among these treatments, the off-label use of hydroxychloroquine (HCQ), a less toxic derivate of chloroquine, has become a common practice among clinicians, including pediatricians, despite lack of evidence of its clinical efficacy for this indication (especially for pediatric patients) at present time (2). 1 Among these treatments, the off-label use of hydroxychloroquine (HCQ), a less toxic derivate of chloroquine, has become a common practice among clinicians, including paediatricians, despite lack of evidence of its clinical efficacy for this indication (especially for paediatric patients) at present time. We would therefore encourage nations where the undertaking of high-quality clinical trials in children during the current SARS-CoV-2 pandemic is possible, to ensure that putative treatments that would be available and affordable in low-to middle-income countries (LMICs), such as hydroxychloroquine, are included wherever possible. At a time of great uncertainty, evidence is urgently needed to inform treatment options, and therefore, randomised controlled trials are necessary to clarify further the clinical benefit of HCQ in paediatric patients with SARS-CoV-2 infections.	./cache/cord-280697-tovty20e.txt	./txt/cord-280697-tovty20e.txt